Application

PF-562,271 has been used as a focal adhesion kinase (FAK) inhibitor to study its effects on the S100A9-induced tumor cell invasion in prostate cancer cell lines. It has also been used to study its effects on syndecan-1 (SDC-1) knockdown-induced upregulation of early growth regulator 1 (EGR1) in colon cancer cells.

Biochem/physiol Actions

PF-562,271 is a potent, ATP-competitive, reversible and selective inhibitor of FAK and Pyk2. PF-562,271 inhibits FAK phosphorylation in vivo.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.